Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12). Chavez JC, Dickinson M, Munoz J, Ulrickson ML, et al. Blood 2025 Feb 12:blood.2024027347. doi: 10.1182/blood.2024027347.

Read + Share

Amedeo Smart

Independent Medical Education

Chavez JC, Dickinson M, Munoz J, Ulrickson ML, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12). Blood 2025 Feb 12:blood.2024027347. doi: 10.1182/blood.2024027347.
PMID: 39938019